Clinical study on continuous oral dosing of etopside combined with prednisone in the treatment of elderly patients with unspecific peripheral T-cell lymphoma
10.3760/cma.j.issn.1009-9921.2014.05.009
- VernacularTitle:依托泊苷联合泼尼松持续口服治疗老年人非特异性外周T细胞淋巴瘤
- Author:
Qiumin YANG
;
Chunli LIN
;
Chunxiang FAN
- Publication Type:Journal Article
- Keywords:
Unspecific peripheral T-cell lymphoma;
Elderly;
Etoposide;
Prednisone;
Drug therapy,combination
- From:
Journal of Leukemia & Lymphoma
2014;23(5):291-293
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and toxicity of etoposide combined with prednisone (EtoP regimen) for elderly patients with unspecific peripheral T-cell lymphoma (PTCL-U) compared with the CHOP regimen.Methods 23 elderly PTCL-U patients were randomly assigned to EtoP group (n =12) or CHOP group (n =11).The curative effects and the adverse reactions were analyzed and compared between the two groups by Log-rank test and x2 test.Results The overall response (OR) rate was 66.67 ％ (8/12) in EtoP group and 63.64 ％ (7/11) in CHOP group.There was no statistically significant difference between the two groups(x2 =0.023,P =0.879).The progression-free survival (PFS) was 7.55 months in EtoP group and 4.38 months in CHOP group,statistically significant difference were observed between the two groups (x2 =23.000,P =0.011).The overall survival (OS) was 15.02 months in EtoP group and 12.26 months in CHOP group,no statistically significant difference was observed between the two groups (x 2 =14.985,P =0.597).The main side effects were bone marrow depression and digestive tract toxicity,no hematology toxicity and digestive tract toxicity of grade Ⅲ-Ⅳ occurred in EtoP group.Of those in CHOP group were 36.36 ％ and 27.27 ％.Conclusion For elderly PTCL-U patients,EtoP regimen is an effective and well tolerated therapeutic schedule.
